Schautzer F - Search Results

1

Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event.

Berger T, Rubner P, Schautzer F, Egg R, Ulmer H, Mayringer I, Dilitz E, Deisenhammer F, Reindl M. Berger T, et al. Among authors: schautzer f. N Engl J Med. 2003 Jul 10;349(2):139-45. doi: 10.1056/NEJMoa022328. N Engl J Med. 2003. PMID: 12853586 Free article.

2

Smoking is a risk factor for early conversion to clinically definite multiple sclerosis.

Di Pauli F, Reindl M, Ehling R, Schautzer F, Gneiss C, Lutterotti A, O'Reilly E, Munger K, Deisenhammer F, Ascherio A, Berger T. Di Pauli F, et al. Among authors: schautzer f. Mult Scler. 2008 Sep;14(8):1026-30. doi: 10.1177/1352458508093679. Epub 2008 Jul 16. Mult Scler. 2008. PMID: 18632775

3

A novel and rapid assay for the detection of neutralizing antibodies against interferon-beta.

Kob M, Harvey J, Schautzer F, Kascha S, Bibl D, Egg R, Reindl M, Berger T, Deisenhammer F. Kob M, et al. Among authors: schautzer f. Mult Scler. 2003 Feb;9(1):32-5. doi: 10.1191/1352458503ms889oa. Mult Scler. 2003. PMID: 12617265

4

Influence of interferon-beta therapy switching on neutralizing antibody titres: results from the Austrian Switch Study.

Gneiss C, Koudouovoh-Tripp PM, Ropele S, Gotwald T, Ehling R, Lutterotti A, Aichner F, Ladurner G, Eggers C, Schautzer F, Künz B, Millonig A, Aspeck E, Reindl M, Berger T, Fazekas F, Deisenhammer F. Gneiss C, et al. Among authors: schautzer f. Mult Scler. 2009 Dec;15(12):1481-8. doi: 10.1177/1352458509347153. Epub 2009 Nov 13. Mult Scler. 2009. PMID: 19965519 Clinical Trial.

5

Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development.

Hegen H, Millonig A, Bertolotto A, Comabella M, Giovanonni G, Guger M, Hoelzl M, Khalil M, Killestein J, Lindberg R, Malucchi S, Mehling M, Montalban X, Polman CH, Rudzki D, Schautzer F, Sellebjerg F, Sørensen PS, Deisenhammer F. Hegen H, et al. Among authors: schautzer f. Mult Scler. 2014 Apr;20(5):577-87. doi: 10.1177/1352458513503597. Epub 2013 Sep 5. Mult Scler. 2014. PMID: 24009164

6

Cytokine profiles show heterogeneity of interferon-β response in multiple sclerosis patients.

Hegen H, Adrianto I, Lessard CJ, Millonig A, Bertolotto A, Comabella M, Giovannoni G, Guger M, Hoelzl M, Khalil M, Fazekas F, Killestein J, Lindberg RL, Malucchi S, Mehling M, Montalban X, Rudzki D, Schautzer F, Sellebjerg F, Sorensen PS, Deisenhammer F, Steinman L, Axtell RC. Hegen H, et al. Among authors: schautzer f. Neurol Neuroimmunol Neuroinflamm. 2016 Jan 27;3(2):e202. doi: 10.1212/NXI.0000000000000202. eCollection 2016 Apr. Neurol Neuroimmunol Neuroinflamm. 2016. PMID: 26894205 Free PMC article.

7

High-dose intravenous interferon-beta in multiple sclerosis patients with high-titer neutralizing antibodies (HINABS II) - A pilot study.

Hegen H, Guger M, Harrer A, Hoelzl M, Kraus J, Skrobal A, Schautzer F, Schmidegg S, Schocke M, Deisenhammer F. Hegen H, et al. Among authors: schautzer f. Mult Scler Relat Disord. 2014 Mar;3(2):220-6. doi: 10.1016/j.msard.2013.09.001. Epub 2013 Sep 26. Mult Scler Relat Disord. 2014. PMID: 25878009 Free article.

8

Natalizumab treatment reduces fatigue in multiple sclerosis. Results from the TYNERGY trial; a study in the real life setting.

Svenningsson A, Falk E, Celius EG, Fuchs S, Schreiber K, Berkö S, Sun J, Penner IK; Tynergy Trial Investigators. Svenningsson A, et al. PLoS One. 2013;8(3):e58643. doi: 10.1371/journal.pone.0058643. Epub 2013 Mar 21. PLoS One. 2013. PMID: 23555589 Free PMC article. Clinical Trial.

9

4-aminopyridine improves downbeat nystagmus, smooth pursuit, and VOR gain.

Kalla R, Glasauer S, Schautzer F, Lehnen N, Büttner U, Strupp M, Brandt T. Kalla R, et al. Among authors: schautzer f. Neurology. 2004 Apr 13;62(7):1228-9. doi: 10.1212/01.wnl.0000118287.68294.e5. Neurology. 2004. PMID: 15079036 No abstract available.

10

Retraction Note to: Menière's disease: combined pharmacotherapy with betahistine and the MAO-B inhibitor selegiline-an observational study.

Strupp M, Kraus L, Schautzer F, Rujescu D. Strupp M, et al. Among authors: schautzer f. J Neurol. 2020 Apr;267(4):1225. doi: 10.1007/s00415-020-09791-7. J Neurol. 2020. PMID: 32189109

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

17 results

Search Page

Filters